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ABSTRACT
Fueled by massive settlements and concerns about pharmaceutical com-
pany influence over medical practice, the fight over off-label promotion has
become a rancorous one with little middle ground. For some, off-label re-
strictions are both bad law and bad medicine, violating the First Amend-
ment while denying physicians access to crucial information. For others,
the battle pits the very soul of the FDA against the excesses of a profit-
driven marketplace. Far from ameliorating concerns over manufacturer in-
fluence, theNewModel proposed by Bennett et al. would exacerbate them.
TheModel would limit FDA authority to core communications proposing
immediate commercial transactions, giving manufacturers unfettered dis-
cretion over scientific exchanges and nearly free rein over truthful quasi-
commercial communications. Most problematically, the NewModel relies
on the longstanding assumption that truly educational and scientific activ-
ities can be distinguished from simple product promotion – a dichotomy
that exists not only in federal law and professional association codes, but
also underlies the jurisdiction of the federal agencies overseeing the phar-
maceutical sector. Experience invites skepticism that these activities can be
cleanly separated, suggesting that the New Model may simply perpetuate
abusive behaviors without offering concomitant benefits to physicians or
patients.
I. INTRODUCTION
Fueled bymassive settlements under the Civil False Claims Act1 and concerns that the
influence of drug manufacturers now extends beyond marketing to affect the practice
1 31 U.S.C. § 3729 et seq. (2012 & Supp. I 2013).
C© The Author 2015. Published by Oxford University Press on behalf of Duke University School of Law,
Harvard Law School, Oxford University Press, and Stanford Law School. This is an Open Access arti-
cle distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence
(http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distri-
bution of the work, in any medium, provided the original work is not altered or transformed in any way, and that
the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
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of medicine itself, the fight over off-label drug promotion is a rancorous one with little
middle ground. For some, the longstanding Food and Drug Administration (FDA) ef-
forts to restrict off-label communications are both bad law and badmedicine, violating
the First Amendment while denying physicians access to crucial prescribing informa-
tion. For others, this is a battle for the very soul of the FDA, pitting scientific integrity
against the excesses of a profit-driven marketplace.
The limited evidence to date on off-label drug use has only added to the furor. In
2006, Radley et al. reviewed a database of physician–patient encounters involvingmed-
ication therapy, comparing patient diagnoses to recognized drug uses.2 The authors es-
timated that 21 per cent (150 million) of the outpatient prescriptions reviewed had
been written for off-label uses, and that 73 per cent of such uses ‘had little or no sci-
entific support’—yet acknowledged that they might have overlooked uses with some
degree of scientific support falling short of their threshold.3 The study thus offered a
glimpse into the extent of off-label prescribing, and highlighted the importance of dif-
ferentiating between clinically appropriate and inappropriate indications. While some
commentators interpreted the study as evidence of the appalling extent of inappropri-
ate and dangerous off-label prescribing, however, others read it to establish that at least
in some circumstances, off-label use is ‘the norm rather than the exception’.4
Into this fray comes the New Model for regulating drug promotion, proposed by
Bennett et al.5 Seeking to balance the need for FDA oversight with the First Amend-
ment rights of drugmanufacturers to communicate accurate and timely scientific infor-
mation to physicians, theNewModel would limit FDA authority toCoreCommunica-
tions proposing immediate commercial transactions, giving manufacturers unfettered
discretionover ScientificExchanges andnearly free reinover truthful quasi-commercial
Non-Core Communications. Far from ameliorating concerns overmanufacturer influ-
ence, however, theNewModelmightwell exacerbate them—enshrining in law the very
practices that have drawn the most scrutiny.
II. CONCERN OVER INDUSTRY REACH
Drug manufacturers influence medical practice in a variety of ways: through explicitly
promotional efforts such as advertising, through the sharing of scientific information,
and by generating information through medical research. Off-label communications,
by their very nature, cross several of these categories. To the extent the goal is (even-
tually) to sell products, communications seem by definition to ‘promote’ a sale. Even
when communications are more ‘informational’, seeking to convey data to physicians
or payers, they often are undertaken with the hope of convincing those audiences to
2 David C. Radley, Stan N. Finkelstein & Randall Stafford, Off-Label Prescribing Among Office-Based Physicians,
166 ARCH. INT. MED. 1021 (2006).
3 Id. at 1026. See also American Society of Clinical Oncology, Reimbursement for Cancer Treatment: Coverage of
Off-Label Drug Indications, 24 J. CLIN. ONCOL. 3206 (2006) (estimating that half of the uses for cancer drugs
are off-label).
4 Amarin Pharma, Inc. v. U.S. Food & Drug Admin., — F. Supp.3d —, No. 15 Civ. 3588(PAE), 2015 WL
4720039 (S.D.N.Y. Aug. 7, 2015) at 3. But seeMarc A. Rodwin,RootingOut Institutional Corruption toManage
Off-Label Use, 41 J. L. MED. & ETHICS 654, 655–6 (2013) (describing ‘frequent lack of scientific support’ and
arguing that off-label use ‘makes clinical sense as an exception rather than as the rule’).
5 Alan Bennett et al., Back to First Principles: A NewModel for the Regulation of Drug Promotion, 2 J. L. & BIOSCI.
168 (2015).
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prescribe (or pay for) the company’s products.6 Moreover, scientific information often
is generated through studies sponsored or otherwise supported by manufacturers. In
the modern age, then, drug manufacturers function as purveyors of information as well
as of products, and the change may be met with skepticism.
It is impossible to separate the furor over off-label promotion from the ongoing de-
bate regarding the extent of industry influence overmedical practice. By themid-2000s,
medical ethicists had begun to criticize the extensive entanglements between the indus-
try and the medical profession, ranging from gifts both small (free lunches) and lavish
(all-expense-paid trips) to lucrative consultancy agreements, control of clinical stud-
ies, and ghost-written journal articles.7 Presuming that manufacturers would be un-
likely to spend billions of dollars on efforts that were not expected to bear fruit, crit-
ics chronicled the ways in which the industry had adapted social psychology research
to target the most effective interventions—such as using other medical and scientific
professionals as ‘key opinion leaders’ to influence their colleagues’ prescribing behav-
iors.8 Public skepticism of the industry has been heightened by the hundreds of phar-
maceutical fraud settlements in recent years, as well as well-publicized allegations that
manufacturers have withheld unfavorable study results and falsely styled marketing ef-
forts as ‘clinical research’.9
III. THE NEW MODEL AND THE DIFFICULTY OF SEPARATING
MARKETING FROM EDUCATION
The New Model acknowledges that off-label communications may simultaneously
serve different purposes, yet remains anchored by a vision of drug manufacturers func-
tioning as sources of valuable scientific information rather than merely product ven-
dors. The authors argue that ‘[n]ot all manufacturer communications are intended
to propose an immediate commercial transaction for a drug; indeed, many modern
communications by manufacturers are more than promotional and are intended to
provide healthcare professionals with the most accurate, up-to-date medical informa-
tion to inform their medical decision-making’.10 From this premise flows a deceptively
simple proposal: while the FDA would maintain its regulatory authority over Core
6 But see Id. at 28 (‘Although all manufacturer communications may be at least in some part commercially-
motivated, some communications do far more than propose a commercial transaction.’); Rodney A. Smolla,
Off-Label Drug Advertising and the First Amendment, 50 WAKE FOR. L. REV. 81, 99 (2015) (arguing that some
prescription-related information is ‘not commercial in any intrinsic sense, but [is] rather data germane to . . .
medical practice’).
7 See eg HOWARD BRODY, HOOKED: ETHICS, THE MEDICAL PROFESSION, AND THE PHARMACEUTICAL INDUSTRY
(2007); David Grande et al., Effect of Exposure to Small Pharmaceutical Promotional Items on Treatment Prefer-
ences, 169 ARCH. INT. MED. 887 (2009) (concluding that ‘[s]ubtle exposure to small pharmaceutical promo-
tional items influences implicit attitudes toward marketed products among medical students’).
8 See eg Sunita Sah&Adriane Fugh-Berman, Physicians Under the Influence: Social Psychology and Industry Mar-
keting Strategies, 41 J.L.MED. & ETHICS 665 (2013); Sergio Sismondo,Key Opinion Leaders and the Corruption
ofMedical Knowledge:What the Sunshine ActWill andWon’t Cast Light On, 41 J. L.MED. &ETHICS 635 (2013).
9 See eg Sammy Almashat & Sidney Wolfe, Pharmaceutical Industry Criminal and Civil Penalties: An Update,
Sept. 27, 2012, http://www.citizen.org/documents/2073.pdf (last accessed Oct. 30, 2015) (identifying 239
drug company settlements totaling $30.2 billion between 1991 and July 2012); Samuel D. Krumholz, David
S. Egilman & Joseph S. Ross, Study of Neurontin Titrate to Effect, Profile of Safety (STEPS) Trial, 171 ARCH.
INT. MED. 1100 (2010) (concluding that major clinical trial was actually a ‘seeding’ trial designed to increase
prescriptions).
10 Bennett et al., supra note 5 at 3.
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Communications such as package inserts, the agency would have no authority to reg-
ulate Scientific Exchange and Other Exempt Communications, and could only regu-
late Non-Core Communications (including the use of medical liaisons and sponsored
speaker presentations to healthcare professionals) that were ‘false and misleading’—
a concept that would be assessed under a more flexible standard than the substantial
evidence needed to obtain FDA approval of a new indication.11
The authors seek to style the New Model as a response to the clash between mod-
ern communications platforms and the outdated FDA regulatory regime, yet the char-
acterization is not entirely convincing. While electronic media enable manufacturers
to communicate with physicians and patients more quickly and in new ways, the core
nature of those communications is not new. Drug manufacturers seek—both by def-
inition and by the necessities of the for-profit corporate form—to sell their products.
Facebook and Twitter are no guarantees that a manufacturer will enhance its altruistic
scientific profile, anymore than reliance on print manuscripts signaled the opposite. In
short, there is little new about drugmanufacturers seeking to share an ever-wider range
of information with prescribers than that contained in the official labeling, other than
the manner in which communications now take place.
Rather thanproviding an innovative response to those changes in light of recentFirst
Amendment developments, however, theNewModel relies on traditional assumptions
about manufacturer motivations. One of the most striking aspects of pharmaceutical
policy in the United States has been the longstanding belief that truly ‘educational and
scientific’ activities can be separated from simple product promotion.Thedichotomy is
evident in the respective roles of the federal government agencies that oversee the phar-
maceutical sector: the FDAserves as the arbiter of scientific evidence,while theDepart-
ment of Health and Human Services Office of Inspector General (OIG) assures that
the medical care provided toMedicare andMedicaid beneficiaries is not influenced by
improper promotional practices, including financial incentives offered to prescribers.
The authors’ assumption thatmanufacturer activities can be neatly sorted into either
the promotion or science/education category echoes a belief long reflected in federal
law and guidance. Rather than flatly prohibiting industry participation in medical ed-
ucation, for example, the FDA has sought to distinguish activities undertaken to mar-
ket products from those that support truly independent scientific and educational ex-
change. When the agency finalized early guidance on industry support of continuing
medical education (CME) in 1997—the documents that gave rise to the initial First
Amendment challenges12—the agency focused on the extent to which a ‘company is in
a position to influence the presentation of information related to its products or other-
wise transform an ostensibly independent program into a promotional vehicle’.13 Rel-
evant considerations included who controlled the content and selection of speakers,
whether there had been full disclosure of manufacturer funding, whether unapproved
uses were discussed, whether the focus was educational rather than commercial, and
who selected the audience—with particular concern for the involvement of sales and
11 Id. at 35, 45.
12 See egWashington Legal Foundation v. Friedman, 13 F. Supp. 2d 51 (D.D.C. 1998).
13 United States Food and Drug Administration (FDA), Final Guidance on Industry-Supported Scientific and
Educational Activities, 62 Fed. Reg. 64,074, 64,095 (Dec. 3, 1997).
The line between marketing and education  709
marketing personnel.14 A similar distinction appeared in a 1996 guidance document
addressing the distribution of journal reprints and reference texts containing off-label
information, which the agency sought to limit to ‘reprints of articles that represent the
peer-reviewed, published version of original efficacy trials’, as well as ‘sound, authorita-
tive materials that are written, published, and disseminated independent of the com-
mercial interest of a sponsoring company and are not false or misleading’.15 Nearly
20 years later, however, these guidelines remain in flux.16
TheOIGadopted a similar stance in its 2003Compliance ProgramGuidance for Phar-
maceutical Manufacturers. Manufacturers were advised to keep grantmaking separate
from sales and marketing activities, establish grant criteria that did not take product
purchases into account, assure that funded activities were bona fide, and exercise no
control over speakers or presentation content.17 OIG recommended that true research
grants be insulated from sales andmarketing influences, and that research-related con-
tracts with potential prescribers be structured to fit the Anti-Kickback Statute personal
services safe harbor.18 Consistent with this advice, OIG warned that research activities
originating though sales andmarketing efforts would face particular scrutiny.Thus, the
potential conflation of research and sales motivations has been a core concern shared
by both agencies.
Thedichotomyhas also been reflected in the voluntary codes adopted by theAmeri-
canMedical Association (AMA) and themajor pharmaceutical trade associations, par-
ticular regarding support for CME. The AMA’s Guidelines on Gifts to Physicians from
Industry, adopted in 1990 and revised in 2001, warned that educational gifts to physi-
cians must have independent educational value, that company-sponsored clinical in-
vestigatormeetingsmust have a ‘genuine research purpose’, and that conference subsi-
dies should be given to the sponsor rather than to individual attendees.19 The Code of
Medical Ethics warns that ‘financial or in-kind support’ from drug and device compa-
niesmay ‘create[] conditions inwhich external interests could influence the availability
and/or content of’ CME activities.20 Where support is necessary, the Code insists on
‘vigorous efforts . . . to maintain the independence and integrity of educational activi-
ties’, including full disclosureof financial interests and ‘taking steps tomitigate potential
influence. . . ’.21
TheAccreditationCouncil forContinuingMedicalEducation (ACCME)Standards
to Ensure the Independence of CME Activities similarly require CME providers to assure
that program ‘decisions were made free of the control of a commercial interest’ and to
14 Id. at 64,096, 64,099.
15 FDA, Advertising and Promotion; Guidances, 61 Fed. Reg. 52,800, 52,801 (Oct. 8, 1996).
16 The latest revised guidance was issued in 2014. See FDA, Guidance for Industry Distributing Scientific and
Medical Publications on Unapproved New Uses—Recommended Practices, Feb. 2014, http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM387652.pdf (last ac-
cessed Oct. 30, 2015).
17 Office of Inspector General (OIG), Compliance Program Guidance for Pharmaceutical Manufacturers, 68
Fed. Reg. 23,731, 23,735 (May 5, 2003).
18 Id.; 42 C.F.R. § 1001.952(d) (2014) (safe harbor).
19 Council on Ethical and Judicial Affairs (CEJA),Gifts to Physicians from Industry, 265 JAMA501 (1991); CEJA,
Guidelines onGifts to Physicians From Industry: AnUpdate, 47 FOOD&DRUGL. J. 445 (1992);CEJA,Guidelines
on Gifts to Physicians from Industry: An Update, 56 FOOD &DRUG L. J. 27, 33, 35–56 (2001).
20 AMERICANMEDICAL ASSOCIATION, AMACODE OFMEDICAL ETHICS, Op. 9.0115 (Nov. 2011).
21 Id.
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keep promotional activities such as advertisements separate from CME activities (eg
banning corporate logos anddrug tradenames fromeducationalmaterials).22 Likewise,
the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Inter-
actions with Healthcare Professionals, issued in 2002 and updated in 2008, warns that
‘[i]nteractions should be focused on informing healthcare professionals about prod-
ucts, providing scientific and educational information, and supporting medical educa-
tion’. 23 And yet, despite near unanimity about the need to distinguish between scien-
tific and promotional activities, the rate of investigations and settlements indicates the
line is anything but clear.
By exempting Scientific Exchange from FDA oversight and privileging the scientific
over the commercial aspects of Non-Core Communications, Bennett et al. not only
perpetuate the fiction underlying this distinction, but also suggest that the drug man-
ufacturer’s role is primarily scientific and educational. The FDA is misguided, they ar-
gue, in emphasizing the promotional elements of manufacturer distribution of medical
reprints to physicians, an activity ‘intendedprimarily to educate, rather than propose an
immediate sale of the drug’.24 At one level the criticism is correct, of course: unless the
person distributing the reprint is seeking the prescription for him/herself—a situation
raising conflicts too numerous to name—the conversation will not result in a sale on
the spot. Indeed, even a straightforward advertisement does not result in an immediate
drug sale; for that, the patient must obtain the prescription and take it to a pharmacy.
And yet that reprint or advertisement couldwell affectwhether the physician prescribes
the drug for the next patient whowalks through the door. ‘Immediate sale’may be a rel-
evant concept for First Amendment analysis, but it offers an incomplete explanation of
the dynamics of prescription decision-making.
Moreover, the authors’ construction of their categories is not persuasive. For exam-
ple, discussions betweenmedical science liaisons (MSLs) and healthcare professionals
are characterized as Non-Core Communications becauseMSLs are employed to serve
as scientific resources rather than sales representatives, and because they ‘are commu-
nicating to an educated audience of healthcare professionals who have the expertise to
evaluate the merits of the information’ under discussion.25 Yet the literature is replete
with examples of the inordinate influence that scientific andmedical experts may wield
by virtue of their stature and training, particularly when housed in the sales and mar-
keting rather than the research and development department.26 Simply restating the
distinction does notmake it true; experience invites skepticism that these activities can
be cleanly separated, raising the specter that the New Model may simply perpetuate
abusive behaviors without offering concomitant benefits.
22 ACCME, Standards for Commercial Support: Standards to Ensure Independence in CME Activities, Standards
1.1 & 4.3 (Feb. 2012), http://www.accme.org/requirements/accreditation-requirements-cme-providers/
standards-for-commercial-support (last accessed Oct. 30, 2015).
23 PhRMA, Code on Interactions with Healthcare Professionals (2008) at 4, http://www.phrma.org/
sites/default/files/pdf/phrma marketing code 2008.pdf (last accessed Oct. 30, 2015).
24 Bennett et al., supra note 5, at 28. The ‘immediate sale’ requirement is drawn from Supreme Court jurispru-
dence defining commercial speech. See eg Bolger v. Youngs Drug Products Corp., 463 U.S. 60, 66 (1983)
(discussing factors that support commercial nature of speech).
25 Bennett et al., supra note 5, at 41.
26 See eg Sah & Fugh-Berman, supra note 8.
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IV. CONCLUSION
In an ideal world, patients would trust their physicians to prescribe medications solely
on the basis of the availablemedical evidence. Physicians would be able to trust that the
scientific information they received about prescription drugs—whether presented at
professional meetings, published in medical journals, or discussed during sales calls—
was comprehensive, reliable, and unbiased. And drug manufacturers would strive to
increase their sales, but only by selling their products for conditions trulywarranting the
treatment. But we do not live in an ideal world, and it has become abundantly clear that
these assumptions may no longer apply (if indeed they ever did). Drug manufacturers
clearly distribute information as well as products, and the reliability of both has come
into question.
The New Model is grounded in an unfailing belief in the drug industry as a font of
trustworthy scientific information. Yet that belief is belied by recent experience. Per-
haps it oncewas possible to trust that drugmanufacturers embodied science as ‘a priest-
hood, an aristocracy of excellence informed by a deep sense of moral obligation’.27 But
that trust has long been lost, based in no small part on instances where the industry in-
tentionally conflated science and marketing—the very dichotomy on which the New
Model relies. In short, immunizing drug manufacturers from scrutiny by enshrining
into law long-unsatisfactory distinctions is neither good law nor good medicine.
27 LINDA MARSA, PRESCRIPTION FOR PROFITS: HOW THE PHARMACEUTICAL INDUSTRY BANKROLLED THE UNHOLY
MARRIAGE BETWEEN SCIENCE AND BUSINESS 17 (1997).
